Espervita Therapeutics
Espervita Therapeutics is dedicated to discovering metabolic reprogramming therapies for cancer treatment, focusing on areas with significant unmet medical needs such as liver cancer. Led by a team with deep expertise in metabolic reprogramming, drug discovery, and development, the company aims to provide hope for cancer patients through innovative therapies.
Industries
Nr. of Employees
small (1-50)
Patents
Functionalized long-chain hydrocarbon mono- and di-carboxylic acids and their use for the prevention or treatment of disease
US-12252467-B2
View DetailsFunctionalized long-chain hydrocarbon mono- and di-carboxylic acids and their use for the prevention or treatment of disease
US-12180151-B2
View DetailsFunctionalized long-chain hydrocarbon mono- and di-carboxylic acids and derivatives thereof, and their use for the prevention or treatment of disease
US-11737995-B2
View DetailsFunctionalized long-chain hydrocarbon mono- and di-carboxylic acids and derivatives thereof, and their use for the prevention or treatment of disease
US-11730712-B2
View DetailsFunctionalized long-chain hydrocarbon mono- and di-carboxylic acids and their use for the prevention or treatment of disease
US-11267778-B2
View DetailsFunctionalized long-chain hydrocarbon mono- and di-carboxylic acids and their use for the prevention or treatment of disease
US-11098002-B2
View Details
Functionalized long-chain hydrocarbon mono- and di-carboxylic acids and their use for the prevention or treatment of disease
US-12252467-B2
View DetailsFunctionalized long-chain hydrocarbon mono- and di-carboxylic acids and their use for the prevention or treatment of disease
US-12180151-B2
View DetailsFunctionalized long-chain hydrocarbon mono- and di-carboxylic acids and derivatives thereof, and their use for the prevention or treatment of disease
US-11737995-B2
View DetailsFunctionalized long-chain hydrocarbon mono- and di-carboxylic acids and derivatives thereof, and their use for the prevention or treatment of disease
US-11730712-B2
View DetailsFunctionalized long-chain hydrocarbon mono- and di-carboxylic acids and their use for the prevention or treatment of disease
US-11267778-B2
View DetailsFunctionalized long-chain hydrocarbon mono- and di-carboxylic acids and their use for the prevention or treatment of disease
US-11098002-B2
View DetailsProducts
Preclinical metabolic reprogramming therapy candidates for liver cancer
A series of preclinical small-molecule candidates designed to inhibit key metabolic pathways (including ACLY) to impair tumor lipid synthesis, alter tumor microenvironment, increase immune detection and reduce tumor burden in liver cancer models.
Preclinical metabolic reprogramming therapy candidates for liver cancer
A series of preclinical small-molecule candidates designed to inhibit key metabolic pathways (including ACLY) to impair tumor lipid synthesis, alter tumor microenvironment, increase immune detection and reduce tumor burden in liver cancer models.
Services
Identification and preclinical optimization of small-molecule candidates that alter tumor metabolism and microenvironment to reduce proliferation and enhance immune detection.
Cross-functional planning supporting nonclinical, translational, clinical and CMC activities and management of regulatory interactions and submissions.
Program management, electronic document management, and regulatory affairs operations to support submission-ready documentation and compliance workflows.
Identification and preclinical optimization of small-molecule candidates that alter tumor metabolism and microenvironment to reduce proliferation and enhance immune detection.
Cross-functional planning supporting nonclinical, translational, clinical and CMC activities and management of regulatory interactions and submissions.
Program management, electronic document management, and regulatory affairs operations to support submission-ready documentation and compliance workflows.
Expertise Areas
- Cancer metabolism and metabolic reprogramming
- Hepatocellular carcinoma (HCC) and liver cancer biology
- Preclinical model development for oncology and metabolic liver disease
- Small-molecule oncology drug discovery
Key Technologies
- Metabolic reprogramming approaches
- ACLY (ATP-citrate lyase) inhibition as a therapeutic mechanism
- Preclinical in vivo and in vitro liver cancer models
- Translational biomarker-driven development